Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Tetra is moving up on the Dronabinol Approval list

<< Previous

Bullboard Posts

Next >>

Comment by CookeMonsteron Jun 16, 2022 10:46am

97 Views

Post# 34761228

RE:Tetra is moving up on the Dronabinol Approval list

Copper, manganese sulfate, selenious acid, sodium iodide, zinc sulfate	Blood substitutes and perfusion solutions	2021-03	Sandoz Canada Incorporated	Being reviewed under the Submissions Relying on Third-Party Data Guidance
Acetaminophen	Analgesics	2021-04	B. Braun Melsungen AG	Being reviewed under the Submissions Relying on Third-Party Data Guidance
Captopril	Agents acting on the renin-angiotensin system	2021-04	Ethypharm Inc	Being reviewed under the Submissions Relying on Third-Party Data Guidance
Dronabinol	Antiemetics and antinauseants	2021-05	Tetra Bio-Pharma Inc.	Being reviewed under the Submissions Relying on Third-Party Data Guidance